Analysis

Bio-Rad at $345 Fair Value: Stability Suggests Hold, Not Buy

By stockpickr AI | March 1, 2026 | 10 min read

Investment Summary

Bio-Rad, a leader in life science and clinical diagnostics, shows stable performance but faces near-term revenue headwinds, suggesting a neutral to slightly positive long-term outlook based on intrinsic value.

Investment Recommendation

Hold

Fair Value: $345.50

Current Price: $328.11

Upside/Downside: +5.30%

The DCF valuation indicates the stock is currently trading close to its intrinsic value, supported by stable historical performance but muted growth projections.

Key Metrics

  • No metrics available